数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

股本结构

单位:万股
公告日期 2024-02-01 2024-02-01 2023-11-06 2023-11-01 2023-08-07 2023-05-15
证券总股本 138.06 4141.90 4147.71 4141.90 4063.97 3743.49
普通股本 138.06 4141.90 4147.71 4141.90 4063.97 3743.49
优先股 未披露 未披露 未披露 9.62 9.62 未披露
其他 未披露 未披露 未披露 未披露 未披露 未披露
变动日期 2024-02-05 2024-02-01 2023-10-23 2023-09-30 2023-06-30 2023-05-15
注释:中概股证券总股本=普通股股本/ 存托凭证比例

历史变动

公告日期 变动后普通股本(万股) 变动后优先股(万股) 变动原因 变动日期
2024-02-01 138.06 未披露
更多>>
GT Biopharma, Inc. effect a reverse stock split of common stock, at a ratio of 1-for-30. The reverse stock split will become effective at 5:00 p.m. Eastern time, on February 2, 2024.
2024-02-05
2024-02-01 4141.90 未披露 定期报告 2024-02-01
2023-11-06 4147.71 未披露 定期报告 2023-10-23
2023-11-01 4141.90 9.62
更多>>
From June 30, 2023 to September 30, 2023 Issuance of common stock in settlement of accounts payable and accrued expenses Issuance of common stock to an officer and a board member for services
2023-09-30
2023-08-07 4063.97 9.62
更多>>
From March 31, 2023 to June 30, 2023 Issuance of common shares in settlement of vendors payable Issuance of common stock for exercise of Prefunded Warrants
2023-06-30
2023-05-15 3743.49 未披露 定期报告 2023-05-15
2023-05-05 3749.31 未披露 定期报告 2023-05-01
2023-05-15 3688.27 9.62
更多>>
From December 31, 2022 to March 31, 2023 Private placement of common stock Issuance of common shares for services Issuance of common shares in settlement of vendors payable
2023-03-31
2023-03-30 3680.93 未披露 定期报告 2023-03-30
2023-01-04 3900.76 未披露
更多>>
Common Stock offered 3,600,000 shares by the company
2023-01-04
2023-03-30 3272.25 9.62
更多>>
From December 31, 2021 to December 31, 2022 Issuance of common stock as equity compensation to consultants Cancellation of common stock previously issued for services Issuance of common stock in settlement of vendor payable Common stock issued upon conversion of notes payable Cancellation of common stock previously issued to prior CEO Issuance of common stock as equity compensation to officers, employees, and board of directors
2022-12-31
2023-01-04 3250.76 未披露 定期报告 2022-12-30
2022-10-31 3255.77 未披露 定期报告 2022-10-31
2022-10-31 3250.76 9.62
更多>>
From June 30, 2022 to September 30, 2022 Equity compensation to officers, employees, and board of directors Issuance of common shares in settlement of vendor payable Equity compensation to consultants
2022-09-30
2022-08-17 3109.25 未披露 定期报告 2022-08-08
2022-08-15 3069.36 9.62
更多>>
From March 31, 2022 to June 30, 2022 Cancellation of common stock upon settlement with former officer Equity compensation to officers, employees, and board of directors Issuance of common shares for services
2022-06-30
2022-05-16 3050.07 未披露 定期报告 2022-05-16
2022-04-29 3308.62 未披露 定期报告 2022-04-18
2022-05-16 3234.57 9.62
更多>>
From December 31, 2021 to March 31, 2022 Cancellation of common stock Issuance of common shares for common shares issuable Issuance of common shares as equity compensation to officers, employees, and board of directors Issuance of common shares for services
2022-03-31
2022-03-28 3212.28 未披露 定期报告 2022-03-28
2022-03-28 3206.20 9.62
更多>>
From December 31, 2020 to December 31, 2021 Conversion of Preferred Series J-1 to common stock Common shares issued upon mandatory conversion of notes payable and accrued interest Common shares issued upon exercise of warrants Issuance of common stock in public offering, net of cost Issuance of common stock for research and development agreement Issuance of common stock for services Equity compensation to officers, board of directors and employees
2021-12-31
2021-11-10 3058.24 未披露 定期报告 2021-11-12
2021-11-10 3050.83 9.62
更多>>
From June 30, 2021 to September 30, 2021 Common shares issued upon conversion of notes payable Common shares issued upon exercise of warrants Issuance of common stock for services Equity compensation to officers and board of directors
2021-09-30
2021-08-23 3048.22 未披露 定期报告 2021-08-15
2021-08-23 2814.41 9.62
更多>>
From March 31, 2021 to June 30, 2021 Common shares issued upon conversion of notes payable Common shares issued upon exercise of warrants Issuance of common stock for services Equity compensation to officers and board of directors
2021-06-30
2021-05-17 2112.77 未披露 定期报告 2021-05-12
2021-04-22 2860.00 未披露 定期报告 2021-04-22
2021-04-22 2839.40 9.62 定期报告 2021-04-12
2021-05-17 2051.74 9.62
更多>>
From December 31, 2020 to March 31, 2021 Conversion of Preferred Series J to common stock Common shares issued upon conversion of notes payable Common shares issued upon exercise of warrants Issuance of common stock in public offering, net of cost Issuance of common stock for research and development agreement Issuance of common stock for services Equity compensation to officers and board of directors
2021-03-31
2021-02-12 2063.80 未披露 定期报告 2021-02-11
GT Biopharma, Inc. effect a reverse stock split of common stock, at a ratio of 1-for-30. The reverse stock split will become effective at 5:00 p.m. Eastern time, on February 2, 2024.
From June 30, 2023 to September 30, 2023 Issuance of common stock in settlement of accounts payable and accrued expenses Issuance of common stock to an officer and a board member for services
From March 31, 2023 to June 30, 2023 Issuance of common shares in settlement of vendors payable Issuance of common stock for exercise of Prefunded Warrants
From December 31, 2022 to March 31, 2023 Private placement of common stock Issuance of common shares for services Issuance of common shares in settlement of vendors payable
Common Stock offered 3,600,000 shares by the company
From December 31, 2021 to December 31, 2022 Issuance of common stock as equity compensation to consultants Cancellation of common stock previously issued for services Issuance of common stock in settlement of vendor payable Common stock issued upon conversion of notes payable Cancellation of common stock previously issued to prior CEO Issuance of common stock as equity compensation to officers, employees, and board of directors
From June 30, 2022 to September 30, 2022 Equity compensation to officers, employees, and board of directors Issuance of common shares in settlement of vendor payable Equity compensation to consultants
From March 31, 2022 to June 30, 2022 Cancellation of common stock upon settlement with former officer Equity compensation to officers, employees, and board of directors Issuance of common shares for services
From December 31, 2021 to March 31, 2022 Cancellation of common stock Issuance of common shares for common shares issuable Issuance of common shares as equity compensation to officers, employees, and board of directors Issuance of common shares for services
From December 31, 2020 to December 31, 2021 Conversion of Preferred Series J-1 to common stock Common shares issued upon mandatory conversion of notes payable and accrued interest Common shares issued upon exercise of warrants Issuance of common stock in public offering, net of cost Issuance of common stock for research and development agreement Issuance of common stock for services Equity compensation to officers, board of directors and employees
From June 30, 2021 to September 30, 2021 Common shares issued upon conversion of notes payable Common shares issued upon exercise of warrants Issuance of common stock for services Equity compensation to officers and board of directors
From March 31, 2021 to June 30, 2021 Common shares issued upon conversion of notes payable Common shares issued upon exercise of warrants Issuance of common stock for services Equity compensation to officers and board of directors
From December 31, 2020 to March 31, 2021 Conversion of Preferred Series J to common stock Common shares issued upon conversion of notes payable Common shares issued upon exercise of warrants Issuance of common stock in public offering, net of cost Issuance of common stock for research and development agreement Issuance of common stock for services Equity compensation to officers and board of directors